Educational overview

Antiparasitic Research

Current and emerging research on antiparasitic approaches — from repurposed pharmaceutical drugs to botanical remedies with traditional and scientific backing.

Important disclaimer

The research summaries below are for educational purposes only. They describe ongoing or published scientific studies and do not constitute medical advice. Experimental treatments mentioned here are not approved for general use unless stated otherwise.

Ivermectin beyond parasites

Active clinical trials

Ivermectin, long used as an antiparasitic, is under active investigation for antiviral, anticancer, and anti-inflammatory properties. Researchers at the University of Melbourne and elsewhere have studied its ability to inhibit nuclear transport proteins used by RNA viruses. Separate oncology studies are exploring its role in disrupting cancer cell signaling pathways (Wnt/β-catenin, PAK1). As of 2025, multiple Phase I/II clinical trials are underway for glioblastoma and breast cancer.

Key findings

Inhibits importin α/β nuclear transport — mechanism relevant to viral replication

Demonstrated antiproliferative effects in glioblastoma cell lines (IC50 ~1–5 μM)

Phase II trial (NCT04527991) evaluating ivermectin in combination with standard glioblastoma therapy

Anti-inflammatory effects observed in murine models of neuroinflammation

Mebendazole as an anticancer agent

Phase II trials ongoing

Mebendazole, a common OTC dewormer, has attracted significant research interest as a potential anticancer drug. It disrupts tubulin polymerization — the same mechanism that makes it effective against worms — and this property also inhibits cancer cell division. Studies at Johns Hopkins and the National Cancer Institute have shown activity against colon, lung, and brain cancers. It is being evaluated in combination with standard chemotherapy.

Key findings

Inhibits tubulin polymerization, blocking mitosis in cancer cells

Showed significant activity against KRAS-mutant colon cancer in preclinical models

Phase II trial (NCT01837862) in recurrent glioblastoma showed disease stabilization in some patients

Favorable safety profile — decades of use as a dewormer provide extensive human safety data

Artemisinin derivatives in oncology

Phase I/II trials

Artemisinin, derived from Artemisia annua (sweet wormwood) and the basis of modern malaria treatment, is being studied for anticancer activity. Its mechanism involves iron-dependent generation of reactive oxygen species (ROS) that damage cancer cells, which tend to accumulate iron. Artesunate (an artemisinin derivative) has entered Phase I/II trials for colorectal cancer, hepatocellular carcinoma, and non-small cell lung cancer.

Key findings

Iron-dependent ROS generation selectively damages iron-rich cancer cells

Artesunate Phase II trial in colorectal cancer showed improved 2-year survival in a small cohort

Active against Toxoplasma gondii and Plasmodium in addition to cancer cell lines

Combination with conventional chemotherapy being explored to overcome resistance

Drug resistance in helminths

Active research priority

Resistance to benzimidazole drugs (albendazole, mebendazole) is well-documented in livestock parasites and increasingly reported in human soil-transmitted helminths. The WHO's 2030 roadmap for neglected tropical diseases identifies drug resistance as a critical threat. Research is focused on identifying resistance markers, developing combination therapies, and discovering new drug classes. Tribendimidine and oxantel pamoate are among the most promising new candidates.

Key findings

β-tubulin codon 200 polymorphism is the primary resistance marker in benzimidazole-resistant nematodes

Tribendimidine (China) shows efficacy against hookworm and Ascaris with a novel mechanism of action

Oxantel pamoate highly effective against Trichuris trichiura (whipworm) — a gap in current drugs

WHO recommends combination therapy (albendazole + oxantel pamoate) for mass drug administration programs

Antiparasitics and the microbiome

Preclinical and early clinical

Emerging research is examining how antiparasitic treatments affect the gut microbiome — and vice versa. Some parasites (notably helminths) appear to modulate the immune system in ways that reduce autoimmune and allergic conditions, giving rise to the 'hygiene hypothesis' and experimental 'helminth therapy.' Simultaneously, researchers are studying how gut bacteria influence drug efficacy and parasite survival.

Key findings

Helminth infections correlate with reduced rates of inflammatory bowel disease in epidemiological studies

Trichuris suis ova (pig whipworm) trials for Crohn's disease and ulcerative colitis — mixed results

Gut microbiome composition influences ivermectin bioavailability and efficacy in animal models

Probiotic co-administration shown to reduce Giardia colonization duration in clinical studies

Botanical & holistic antiparasitic approaches

Traditional use / early research

Several plant-derived compounds have a long history of traditional use against intestinal parasites and are now the subject of modern pharmacological investigation. Wormwood (Artemisia absinthium), black walnut hull (Juglans nigra), clove (Syzygium aromaticum), pumpkin seed (Cucurbita pepo), oregano leaf oil (Origanum vulgare), and garlic (Allium sativum) each contain bioactive constituents with demonstrated in vitro or animal-model antiparasitic activity. Evidence quality varies — most human data comes from small trials or observational studies. None are approved as standalone treatments for parasitic infections, and none should replace prescribed therapy. They are best understood as adjuncts under professional guidance.

Key findings

Wormwood (Artemisia absinthium): contains absinthin and thujone; in vitro activity against Ascaris and Giardia; related compound artemisinin (from A. annua) is the basis of WHO-approved malaria therapy

Black walnut hull (Juglans nigra): juglone and tannins show anthelmintic activity against intestinal worms in animal models; limited controlled human data

Clove (Syzygium aromaticum): eugenol disrupts parasite cell membranes; demonstrated activity against Giardia lamblia and Toxoplasma gondii in vitro

Pumpkin seed (Cucurbita pepo): cucurbitacin and amino acid cucurbitin paralyze tapeworm musculature; small human trials show modest efficacy against Taenia spp.

Oregano leaf oil (Origanum vulgare): carvacrol and thymol show broad antimicrobial and antiparasitic activity; pilot study (Force et al., 2000) reported Blastocystis and Entamoeba clearance in 8 of 11 patients

Garlic (Allium sativum): allicin and ajoene demonstrate activity against Giardia, Trypanosoma, and Leishmania in vitro; garlic extract reduced Ascaris egg counts in a small animal study

Fenbendazole and cancer (Joe Tippens protocol)

Phase II trial (South Korea)

Fenbendazole, a veterinary dewormer, gained widespread attention after Joe Tippens reported a remarkable recovery from stage 4 small cell lung cancer in 2016 while taking fenbendazole alongside other supplements. Subsequent laboratory studies have shown fenbendazole disrupts microtubule formation, inhibits glucose uptake (GLUT transporters), and induces apoptosis in cancer cell lines. Formal clinical trials are now underway in South Korea and elsewhere.

Key findings

Inhibits tubulin polymerization and GLUT1/GLUT4 glucose transporter expression in cancer cells

Demonstrated activity against colorectal, lung, and prostate cancer cell lines in vitro

South Korean Phase II trial (NCT04842994) evaluating fenbendazole in non-small cell lung cancer

Synergistic effects observed when combined with vitamins E succinate and B12 in preclinical models

Do not self-treat

Research summaries are provided for educational purposes only. Do not use experimental findings to self-treat or alter prescribed treatments. Always consult a qualified healthcare or veterinary professional before making any medical decisions.